Panion in ITF-meeting at EMA

Development of new and unique medicines for animals (and humans) requires a close cooperation with the authorities that in the end will decide on the approval and allow marketing of the product.

In Europe, genetically based novel medicines are authorised by application to the European Medicines Agency (EMA), currently located in London. To facilitate the understanding of new ideas and approaches to treatment of diseases, the EMA has established an Innovation Task Force (ITF) which consists of experienced scientific reviewers and persons involved in the assessment and processing of new medicinal inventions, who will meet with a small number of selected companies each year.

Panion's epilepsy product, which is based on CombiGene's scientific development over many years, was accepted for an ITF meeting in 2018. A briefing package of background infor- mation and research results was send to EMA before the ITF meeting with the experts in London in June 2018. Associate professor at the University of Copenhagen, David Woldbye, led the scientific questions on the project. Chief Research and Development Officer from CombiGene, Karin Agerman, led the discussion on manufacture and product development.

CEO and veterinarian from Panion, Anja Holm, led the presentation and the clinical discussion on the development of the product for animals.

"The meeting was very successful, and our expectations were fully met. We got some new things to think about and new angles that we can use for the benefit of the product development. It was clear that they understand our approach very well. Importantly, we also got a feeling for where the authorities see potential short-cuts that we will explore, and where we need to investigate and explain more thoroughly", says Anja Holm, CEO of Panion Animal Health AB. 

TUE, JUN 12, 2018

For further information, please contact:

Anja E. H. Holm, CEO | + 45-22 94 66 00 anja.holm@panion-animalhealth.com 

Developing animal health - In Panion, we want to improve the quality of life for animals suffering from chronic diseases. We are convinced that gene therapy has promising prospects. Our aim is to develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, based on CombiGene AB's technology and platform. Panion Animal Health AB is listed at AktieTorget. 

Nerladdningsbara filer

Panion's emission is finalised and the dog safety study is progressing well

Panion's shares emission that was running from 16-30 May and raised appr. 5.2 MSEK before emission costs, has now been completed and all payments processed.





Nyemission registrerad hos Bolagsverket

Panion Animal Health AB:s (publ) nyemission är nu delregistrerad hos Bolagsverket


Panion's dog safety study experience a slight delay

Panion Animal Health AB develops a unique gene therapy treatment for dogs with idiopathic epilepsy. A safety study in dogs is currently running at the University of Copenhagen under the lead of Associate Professor David Woldbye, Department of Neuroscience, KU. Preliminary results from the study were expected in Q2, but due to circumstances outside Panion's influence, Panion has just been informed that this timing has been slightly delayed into Q3.


Panion presented at InvestorDagen in Århus, Denmark, the 12.th of June 2018

The progress and plans for Panion's development of the gene therapy treatment for dogs with epilepsy, and for Panion's business idea and vision, was presented by Anja Holm, CEO of Panion, at the InvestorDagen event in Århus, Denmark on the 12.th of June.


Panion in ITF-meeting at EMA


Panion presents for investors at InvestorDagen in Aarhus, DK on the 12.th of June 2018

Panion Animal Health AB is a Swedish registered company with shares on Spotlight/AktieTorget and with a unique product in development - a gene therapy treatment for epilepsy in dogs. We have  a strong Scandinavian cooperation in that half of Panion's management and board resides in Denmark. A safety study in dogs is currently running in Denmark in cooperation with the University of Copenhagen and under the lead of Associate professor David Woldbye, Department of neuroscience, KU.


Slutligt utfall i Panions nyemission

Panion Animal Health AB:s (publ) ("Panion") nyemission av units tecknades till cirka 56 procent och Panion tillförs därigenom en emissionslikvid om cirka 5,2 miljoner kronor före avdrag för emissionskostnader.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90
Kontaktformulär

Kontakta oss

Vill du veta mer om beQuoted och våra tjänster så fyll i nedanstånde uppgifter och tryck skicka.

En av våra rådgivare kontaktar dig inom kort.

Namn: Telefon: E-postadress: Meddelande: